New REDUCE-IT® Analyses Show VASCEPA® (icosapent e

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

New REDUCE-IT® Analyses Show VASCEPA® (icosapent ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United Arab Emirates , Ireland , Philadelphia , Pennsylvania , United States , Spain , Finland , Switzerland , Netherlands , Denmark , United Kingdom , Austria , Sweden , China , Lebanon , Canada , Dublin , New Jersey , Scotland , Great Britain , American , Americans , Clin Cardiol , Coll Cardiol , Mark Marmur , Exchange Commission , Amarin Corporation , Nasdaq , Drug Administration , European Union , A Report From The American Heart Association , American Heart Association , Analyses Show , Relative Risk Reduction Compared , Prespecified Subgroup , Metabolic Syndrome , Without Diabetes , Total Events Compared , Almost Exclusively Comprised , Established Cardiovascular , Scientific Data , Clinical Use , Reduce Cardiovascular , Presented Today , Scientific Sessions , Simultaneously Published , European Heart Journal , New England Journal , United Arab , Private Securities Litigation Reform Act , Securities Act , Clinic Metabolic Syndrome , Its Individual Components , Renal Function , Heart Disease , Stroke Statistics , Report From , American Heart , Cardiovascular Events , Icosapent Ethyl , Cardiovascular Risk Reduction , Total Ischemic Events ,